

Accepted Manuscript



Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study

Tristram Smith, PhD, Michael G. Aman, PhD, L. Eugene Arnold, MD, Laura B. Silverman, PhD, Luc Lecavalier, PhD, Jill Hollway, PhD, Rameshwari Tumuluru, MD, Susan L. Hyman, MD, Kristin A. Buchan-Page, BS, Jessica Hellings, MD, Robert R. Rice, Jr., PhD, Nicole V. Brown, MS, Xueliang Pan, PhD, Benjamin L. Handen, PhD

PII: S0890-8567(16)31119-4

DOI: [10.1016/j.jaac.2016.06.015](https://doi.org/10.1016/j.jaac.2016.06.015)

Reference: JAAC 1588

To appear in: *Journal of the American Academy of Child & Adolescent Psychiatry*

Received Date: 10 February 2016

Revised Date: 31 May 2016

Accepted Date: 25 June 2016

Please cite this article as: Smith T, Aman MG, Arnold LE, Silverman LB, Lecavalier L, Hollway J, Tumuluru R, Hyman SL, Buchan-Page KA, Hellings J, Rice Jr. RR, Brown NV, Pan X, Handen BL, Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study, *Journal of the American Academy of Child & Adolescent Psychiatry* (2016), doi: 10.1016/j.jaac.2016.06.015.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study

RH: Extension Study of Children With Autism and ADHD

Tristram Smith, PhD, Michael G. Aman, PhD, L. Eugene Arnold, MD, Laura B. Silverman, PhD, Luc Lecavalier, PhD, Jill Hollway, PhD, Rameshwari Tumuluru, MD, Susan L. Hyman, MD, Kristin A. Buchan-Page, BS, Jessica Hellings, MD, Robert R. Rice, Jr., PhD, Nicole V. Brown, MS, Xueliang Pan, PhD, Benjamin L. Handen, PhD

Supplemental material cited in this article is available online.

Accepted July 27, 2016

Drs. Smith, Silverman, and Hyman are with the Division of Neurodevelopmental and Behavioral Pediatrics at the University of Rochester, Rochester, NY. Drs. Aman, Arnold, Lecavalier, Hollway, and Hellings are with the Nisonger Center UCEDD, The Ohio State University, Columbus. Drs. Tumuluru and Handen are with University of Pittsburgh School of Medicine. Mss. Buchan-Page and Brown and Drs. Rice and Pan are with the Center for Biostatistics, The Ohio State University.

This work was supported by grants from the National Institute of Mental Health to Ohio State University (5R01MH079080), University of Pittsburgh (5R01MH079082-05), and University of Rochester (5R01 MH083247), by Eli Lilly and Co., who provided atomoxetine and placebo, by the University of Rochester CTSA (UL1 RR024160) and the Ohio State University CTSA (UL1TR001070), from the National Center for Research Resources, and the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).

This study was presented as a poster at the International Meeting for Autism Research, Salt Lake City, UT, May 13-16, 2015.

Dr. Pan served as the statistical expert for this research.

The authors gratefully acknowledge the guidance and supervision of the data safety monitoring board, consisting of Edwin H. Cook, Jr., MD (University of Illinois at Chicago), Walter J. Meyer, MD (University of Texas-Galveston), Carson R. Reider, PhD (Ohio State University), and Wesley K. Thompson, PhD (University of California-San Diego).

Disclosure: Dr. Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for AMO Pharma Ltd., CogState, Inc., Confluence Pharmaceutica, CogState Clinical Trials, Ltd., Coronado Biosciences, Forest Research, Hoffman-La Roche, Lumos Pharma, MedAvante, Inc., ProPhase LLC, and Supernus Pharmaceuticals. Dr. Arnold has received research funding from Curemark, Forest, Eli Lilly and Co., Neuropharm, Novartis, Noven, Shire, Supernus, YoungLiving, NIH, and Autism Speaks;

Download English Version:

<https://daneshyari.com/en/article/4931618>

Download Persian Version:

<https://daneshyari.com/article/4931618>

[Daneshyari.com](https://daneshyari.com)